Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Azacitidine Maintenance in AML Patients Undergoing Reduced Intensity AlloHSCT
NCT07548983Phase 1Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib and azacitidine in acute myeloid leukemia (AML), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Incidence of dose limiting toxicities at 2 months and Incidence of grade 3+ treatment-related adverse events at 9 months. Started Apr 2026; status: recruiting.
02
Drugs
ruxolitinibazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07548983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07548983.